In a report issued 8/15/2016 JPMorgan increased the target price of Patheon N.V. (NYSE:PTHN) by 0.11% from $0 to $30
On 8/15/2016, KeyBanc released a statement for Patheon N.V.(NYSE:PTHN) suggesting “Overweight” with a target price of $33 that suggested an upside of 0.22%.
Having a price of $27.00, Patheon N.V. (NYSE:PTHN) traded 4.41% higher on the day. With the last close up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased 0.00% over the same time period. PTHN has been tracking to a 50-day moving average of $0.00 and 200-day average of $0.00. 299,142 shares of Patheon N.V. were exchanged, up from an average trading volume of 0
Recent Performance Graphic:
Patheon N.V. has a one-year low of $25.52 and a one-year high of $27.43 and has a market capitalization of $N/A.
General Information About Patheon N.V. (NYSE:PTHN)
Patheon Holdings CoÃ¶peratief U.A. provides outsourced pharmaceutical development and manufacturing services. The company offers a range of active pharmaceutical ingredient and finished drug product services, including formulation development, as well as clinical and commercial-scale manufacturing, packaging, and lifecycle management. It caters to small molecule and large molecule biological drugs sectors.Patheon Holdings CoÃ¶peratief U.A. was incorporated in 2013 and is based in Amsterdam, and the Netherlands.